Cue Biopharma, Inc. (CUE) vs Keros Therapeutics, Inc. (KROS)
Cue Biopharma, Inc. and Keros Therapeutics, Inc. are both Biotechnology companies. Cue Biopharma, Inc. and Keros Therapeutics, Inc. are of similar size ($238.6M and $229.0M). Cue Biopharma, Inc. grew revenue faster over the last twelve months: 354.4% against −84.6%. Keros Therapeutics, Inc. has the higher net margin (0.00% vs −435.8%) and the lower return on invested capital (−1,345.3% vs 0.00%). Across the 16 metrics below, Keros Therapeutics, Inc. leads on 13 and Cue Biopharma, Inc. on 3.
Valuation
Profitability
| Metric | CUE | KROS | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (262.03%) | 0.00% | 0.00% |
| Net margin | (435.83%) | 0.00% | 0.00% |
| Free cash flow margin | (133.13%) | 0.00% | 0.00% |
| Return on equity | (1,603.48%) | (17.16%) | (57.72%) |
| Return on assets | (459.60%) | (15.92%) | (49.22%) |
| Return on invested capital | 0.00% | (1,345.30%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack